Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00026897 · ClinicalTrials.gov registry record · Phase 2
Trafficking of Indium-III-Labeled Cultured Immune Cells in Patients Undergoing Immunotherapy for Advanced Cancer
A Phase 2 study of Neoplasm, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT00026897 is a Phase 2 study of Neoplasm that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 100 participants, below the 193-participant average among 11 other Neoplasm trials with a reported enrollment target (48% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00026897, a Phase 2 study of Neoplasm, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients undergoing immunotherapy for advanced cancer under IRB-approved protocols, who are to receive immune cells in adoptive transfer, will have less than or equal to 50% of those cells labeled with In-111-oxine and administered along with the remainder of their unlabeled cells. They will then undergo gamma-camera imaging over the next 0-7 days and blood samples and tumor sites which are accessible with minimal surgery (low-risk biopsy) may be sampled in some patients for enumeration of radiolabeled cells. End-points will be tumor and normal organ imaging and the amount of In-111 per gram of tissue in biopsies or per ml. of blood.
Conditions Studied
Interventions
- PROCEDURE Gamma-camera imaging
- PROCEDURE Low-risk biopsy
Study Locations (1)
Maryland
- National Cancer Institute (NCI) - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 1997-12 |
| Est. Completion | 2002-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00026897
The ClinicalTrials.gov registry entry for NCT00026897 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 193-participant average among 11 other Neoplasm trials with a reported enrollment target (48% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Gamma-camera imaging is the first listed.
NCT00026897 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00026897 about?
NCT00026897 is a clinical study titled "Trafficking of Indium-III-Labeled Cultured Immune Cells in Patients Undergoing Immunotherapy for Advanced Cancer". Patients undergoing immunotherapy for advanced cancer under IRB-approved protocols, who are to receive immune cells in adoptive transfer, will have less than or equal to 50% of those cells labeled with In-111-oxine and administered along with the remainder of their unlabeled cells. They will then un...
What is the current status of trial NCT00026897?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 1997-12. Estimated completion is 2002-12.
What conditions does trial NCT00026897 study?
This clinical trial studies the following conditions: Neoplasm.
What interventions are being tested in trial NCT00026897?
The interventions under investigation include: Gamma-camera imaging (PROCEDURE), Low-risk biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT00026897?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00026897 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Karenitecin (BNP1350) to Treat Malignant Melanoma
COMPLETED · Phase 2
-
A Pilot Study to Investigate the Clinical Utility of the Peregrine Monte Carlo Dose Calculation System for Radiation Therapy Treatment Planning
COMPLETED · Phase 2
-
CARE Study: Cancer, Asian Americans, and Relationship Enrichment
RECRUITING · NA
-
A Nature-Based Virtual Reality (VR) Intervention in Family Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients
RECRUITING · NA
-
A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study of LY2835219 in Participants With Cancer
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.